Not registered yet? Please contact our project manager Dr. Mary Gazea . This area is only for members of the research consortium.


23 September 2022

Watch our mini-video series from #ILC2022

Following the patients’ interest in DECISION, we tried something new during the International Liver Congress (ILC) in London in June 2022, namely recording several video interviews by representatives of the European Liver Patients’ Association (ELPA) with our scientific coordinator Prof. Dr. Pierre-Emmanuel Rautou. And because we were on a roll, the new concentris team member Dennis Cleff also interviewed Prof. Dr. Sara Montagnese (UNIPD) about the symptoms of decompensated cirrhosis via Zoom shortly thereafter. Watch all videos here.

More news


19 - 21 October 2022

4th General Assembly (GA) meeting in Madrid

The DECISION consortium is looking forward to meet again face-to-face from 19-21 October 2022 in Madrid. This meeting will have a strong focus on results and paper-writing and it will serve to discuss the final steps before the start of the COMBAT trial later this year. 45 registered members will join forces to make progress on combinatorial therapies for patients with decompensated cirrhosis.

More events

Our Vision

DECISION strives to better understand the pathophysiology of decompensated cirrhosis leading to acute-on-chronic liver failure (ACLF) at the systems level by taking advantage of already existing large and clinically well characterized patient cohorts. The ultimate goal is to significantly reduce mortality through combinatorial therapies that are tailored to the specific needs of individual patients. Part of this endeavour is to develop a reliable prognostic test and a robust response test.

Learn more

Why it matters

In 2013, cirrhosis was responsible for 1.2 million deaths worldwide. While most cirrhosis patients initially do not show symptoms, acute decompensation of cirrhosis, defined as the body’s inability to cope with the progressing dysfunctionality of the liver, leads to drastic symptoms. Decompensation is characterized by the development of ascites, hepatic encephalopathy, jaundice, or gastrointestinal haemorrhage, and is often a turning point for cirrhosis.

Learn more